Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 2, 2006, Pages 64-70

  Sauron, R ^a   Wilkins, M ^b   Jessent, V ^a   Dubois, A ^a   Maillot, C ^a   Weil, A ^c  

^a Laboratoires Fournier SA   (France)

^b Department of Pharmaceutical Sciences   (Ireland)

^c Avogadro   (France)

Author keywords

Bioavailability; Fenofibrate; Food interaction; Nanoparticle formulation

Indexed keywords

FENOFIBRATE; NANOPARTICLE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FOOD DRUG INTERACTION; GEOMETRY; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; LIPID DIET; LOW FAT DIET; MALE; MEAL; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION;

EID: 32544458008     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44064     Document Type: Article

References (11)

1. Abbott Laboratories 1999 A comparative study of the effect of food on the bioavailability of fenofibric acid from a 160 mg tablet formulation of fenofibrate with that from a capsule formulation of fenotibrate. Internal Report R&D/99/078, Protocol M98-962
2. Abbott Laboratories 2003 A comparative study of the bioavailability of fenofibric acid from two fenofibrate tablet dosage strengths (145 mg and 48 mg) relative to that from a reference 200 mg fenofibrate capsule. Internal Report R&D/03/470, Protocol M02-558
3. Balfour JA, McTavish D, Heel RC 1990 Fenofibrate - A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40: 260-290
4. Desager JP, Harvengt C 1978 Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug in volunteers. J Clin Pharmacol Biopharm 16: 570-574
5. Gotto AM, Brinton EA 2004 Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease - A working group report and update. JACC 43: 717-724
6. Grundy SM 2002 Low-density lipoprotein, non-high density lipoprotein and apolipoprotein B as target of lipid-lowering therapy. Circulation 106: 2526-2529
7. Laboratoires FOURNIER S.A. 2002 A comparative study of the effect of food on the bioavailability of fenofibric acid from a test 160 mg formulation of fenofibrate with that from a reference 200 mg capsule formulation of fenofibrate, after a single dose, in 18 healthy male subjects. Internal Report K 178P 02 05 KH 03 02
8. Laboratoires FOURNIER S.A. 2003a Investigation of a possible pharmacokinetic interaction between fenofibrate and atorvastatin following multiple dose administration in healthy male volunteers. Internal Report K178 0201 KH 03 02
9. Laboratoires FOURNIER S.A. 2003b Food-effect bioavailability study of fenofibric acid from a 145 mg tablet formulation of fenofibrate. Internal Report K LF 178P 02 06 KH 03 02
10. Laboratoires FOURNIER S.A. 2003c Comparative bioavailability study of a 145 mg tablet formulation of fenofibrate versus a 160 mg tablet formulation of fenofibrate after single dose in healthy male subjects. Internal Report K LF178P 02 07 KH 03 02
11. Strolin-Benedetti M, Guichard JP, Vidal R, Donath A 1986 Kinetics and metabolic fate of 14C-fenofibrate in human plasma. Acta Pharmacol Toxicol 59: 167